Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Zomedica Corp. Common Shares
(NY:
ZOM
)
0.0973
UNCHANGED
Last Price
Updated: 8:00 PM EST, Mar 4, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Zomedica Corp. Common Shares
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Ignore Zomedica’s Recent Struggles. The Road Ahead Remains Bright.
↗
July 19, 2021
ZOM stock has come under price pressure recently, but the outlook is bright as Zomedica plots a road map to success.
Via
InvestorPlace
Speculative Investors Are Crazy Not to Buy Zomedica at Its Current Prices
↗
July 15, 2021
Under 75 cents, ZOM stock is a penny stock worth betting on
Via
InvestorPlace
Wait for Zomedica to Give Up More of its Meme Stock Gains
↗
July 15, 2021
It's not there yet, but if ZOM stock pulls back another 50% or so, the risk/return proposition will be more in your favor.
Via
InvestorPlace
Zomedica Stock Still Has a Rocky Few Months Left Ahead of It
↗
July 14, 2021
ZOM stock is rife with massive potential. But it's the same potential that has gone unfulfilled for the past few months.
Via
InvestorPlace
A Little Patience Could Go a Long Way For ZOM Stock
↗
July 12, 2021
Now that Truforma is in the market, it’s time for investors to see revenue growth
Via
InvestorPlace
2 Risky Meme Stocks You Don't Want to Hold With 'Diamond Hands'
↗
June 29, 2021
Some stocks you can buy and forget. With Zomedica and ContextLogic, you'll want to keep a much closer eye on matters.
Via
The Motley Fool
Wait for the Reddit Set to Sell Before Buying Bionano Stock
↗
June 28, 2021
Genomics play BNGO stock may pay off down the road, but wait for a meme stock investor exodus before making it a buy
Via
InvestorPlace
Zomedica Is Way Undervalued Here as Its Gear Is Catching On
↗
June 28, 2021
InvestorPlace’s Mark Hake estimates Zomedica is worth between $1.11 and $1.61 a share. That makes ZOM stock a buy. Here’s why I agree.
Via
InvestorPlace
Radio Silence May Indicate a Problem for Zomedica Stock
↗
June 24, 2021
Zomedica is due to report results for the current quarter on Aug. 11. Until then, investors have nothing with which to weigh ZOM stock.
Via
InvestorPlace
Zomedica Stock Has More Headwinds Than the Rest of the Pet Industry
↗
June 23, 2021
Drilling into pet industry details reveals a key risk factor that some ZOM stock believers may be ignoring.
Via
InvestorPlace
Risk-Reward Ratio of Zomedica Stock Looks Unfavorable
↗
June 17, 2021
Zomedica may be facing tough competition, and there are indications that Truforma is not popular so far. ZOM stock looks very risky.
Via
InvestorPlace
Zomedica Pharmaceuticals Has to Prove Itself to Long-Term Investors
↗
June 16, 2021
The hype surrounding ZOM stock has worn off, and it's now time for the company to prove its value through its sales numbers.
Via
InvestorPlace
Zomedica Is Good Value and May Be Worth $1.36 — Or More
↗
June 15, 2021
Zomedica is good value and is on the acquisition warpath. ZOM stock is worth $1.36 on average, providing an average 20% ROI over 2 years.
Via
InvestorPlace
Zomedica Is Surprisingly Cheap Even as Commercialization Commences
↗
June 14, 2021
ZOM stock has spiked sharply this year, but a recent price pullback could signal an ideal entry point for pet care market investors.
Via
InvestorPlace
Better Robinhood Penny Stock: Sundial Growers vs. Zomedica
↗
June 05, 2021
Both have been huge winners in recent months.
Via
The Motley Fool
Zomedica’s Risks Are Too Big to Ignore
↗
June 02, 2021
You may like ZOM stock as a pet lover, but not for its fundamentals, nor its valuation until it starts having credible financial results.
Via
InvestorPlace
Zomedica’s High Share Count Creates Challenges for ZOM Stock
↗
June 02, 2021
Zomedica has promising growth potential, but its high share count makes ZOM stock a risky investment. Here's what investors should know.
Via
InvestorPlace
Topics
Bonds
Zomedica Stock Will Be Worth The Risk After Another Drop
↗
June 01, 2021
Another pullback in ZOM stock will put this long-term speculative play's odds in your favor if its Truforma product catches on.
Via
InvestorPlace
Right-Priced Zomedica Could Be an Investor’s Best Friend
↗
June 01, 2021
The skeptics might misinterpret the company's first-quarter revenue data, but a deeper dive should uncover reasons to hold on to ZOM stock.
Via
InvestorPlace
Social Distancing Creates Pet-Buying Boom that Sends the Industry to New Heights
June 01, 2021
Via
FinancialNewsMedia
Bets on Zomedica’s In-Office Vet Test Could Payoff or Bust by Year-End
↗
May 27, 2021
ZOM stock is pure speculation as pet owners are spending more on keeping their dogs and cats alive.
Via
InvestorPlace
Is Zomedica Making a Change For the Better?
↗
May 26, 2021
Wait for evidence of success before making a speculative bet on ZOM stock
Via
InvestorPlace
Zomedica Stock Can Return to a Dollar If It Focuses on Just One Thing
↗
May 24, 2021
Zomedica is testing its support levels at current prices. What does the maker of diagnostic equipment need to do to get ZOM stock back to $1?
Via
InvestorPlace
Zomedica Stock Is At Serious Risk Unless Bulls Commit
↗
May 19, 2021
ZOM stock makes for a better trading vehicle than an investment in spite of their noble effort to heal. It needs to hold recent lows or else.
Via
InvestorPlace
Could Zomedica Be a Millionaire-Maker Stock?
↗
May 19, 2021
Or will speculation lead to major disappointment?
Via
The Motley Fool
Why Zomedica Stock Popped Today
↗
May 17, 2021
A new executive will oversee the company's growth initiatives.
Via
The Motley Fool
Zomedica Stock Will Burn You as High-Growth Stocks Start to Flag
↗
May 17, 2021
The bull market has certainly made new investors look like geniuses, as usual. But now is the true test and ZOM stock isn't likely to pass.
Via
InvestorPlace
Zomedica Stock Is Clearly Going to Keep Moving in the Wrong Direction
↗
May 17, 2021
Zom stock is sliding downward due to its precarious financial situation. With no sales, it's best for investors to steer clear.
Via
InvestorPlace
Zomedica Is Now a Low-Probability Gamble
↗
May 14, 2021
ZOM stock attracts plenty of attention for its underlying pet care business and its wild potential but this game may be over.
Via
InvestorPlace
Zomedica Stock Is Another Hyped-Up Reddit Play That Can’t Escape Reality
↗
May 11, 2021
Zomedica has potential in a niche business. But the price of ZOM stock does not yet reflect that. This will change as day traders move on.
Via
InvestorPlace
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.